

Emily K Bergsland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1319144/publications.pdf>

Version: 2024-02-01

48
papers

3,209
citations

331670

21
h-index

206112

48
g-index

48
all docs

48
docs citations

48
times ranked

4465
citing authors

#	ARTICLE	IF	CITATIONS
1	New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. <i>Abdominal Radiology</i> , 2022, 47, 3078-3100.	2.1	18
2	Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. <i>Pancreatology</i> , 2022, 22, 123-129.	1.1	6
3	Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. <i>Biosensors and Bioelectronics</i> , 2022, 199, 113854.	10.1	10
4	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.	1.6	85
5	Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. <i>Abdominal Radiology</i> , 2022, , 1.	2.1	1
6	Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2818-2829.	1.6	13
7	Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. <i>JCO Precision Oncology</i> , 2022, , .	3.0	4
8	Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 212-221.	1.3	7
9	Assessment and Comparison of ¹⁸ F-Fluorocholine PET and ^{99m} Tc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1285-1291.	5.0	21
10	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
11	The Immunotherapy Landscape in Adrenocortical Cancer. <i>Cancers</i> , 2021, 13, 2660.	3.7	8
12	Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. <i>PLoS ONE</i> , 2021, 16, e0252574.	2.5	5
13	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	1.1	88
14	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	1.1	58
15	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	2.9	1
16	Carcinoid Crisis—Induced Acute Systolic Heart Failure. <i>JACC: Case Reports</i> , 2020, 2, 2068-2071.	0.6	2
17	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	5.0	6
18	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. <i>Pancreas</i> , 2020, 49, 723-728.	1.1	6

#	ARTICLE	IF	CITATIONS
19	A Rare Case of Carcinoid Constrictive Pericarditis. <i>JACC: Case Reports</i> , 2020, 2, 1-5.	0.6	1
20	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
21	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.	1.6	53
22	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1066-1075.	3.7	10
23	Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. <i>Oncologist</i> , 2019, 24, e662-e670.	3.7	8
24	Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1056-1065.	3.7	8
25	Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. <i>Translational Oncology</i> , 2019, 12, 550-560.	3.7	2
26	Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. <i>Modern Pathology</i> , 2019, 32, 290-305.	5.5	45
27	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2702-2709.	4.1	30
28	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 693-702.	4.9	289
29	Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. <i>Medical Oncology</i> , 2017, 34, 88.	2.5	6
30	A Case of Metastatic Atypical Neuroendocrine Tumor with <i>ALK</i> Translocation and Diffuse Brain Metastases. <i>Oncologist</i> , 2017, 22, 768-773.	3.7	33
31	Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. <i>Clinical and Translational Imaging</i> , 2017, 5, 63-69.	2.1	10
32	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 14-23.	1.6	258
33	Radioembolization with ⁹⁰ Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 860-874.	1.4	27
34	Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 63-82.	2.2	8
35	Neuroendocrine Tumors, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 78-108.	4.9	302
36	The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 92-103.	3.8	48

#	ARTICLE	IF	CITATIONS
37	Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. <i>EJNMMI Physics</i> , 2015, 2, 21.	2.7	27
38	Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy. <i>Cell Reports</i> , 2015, 11, 577-591.	6.4	136
39	Is More Not Better?. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 85-116.	2.2	3
40	A phase II study of axitinib in advanced carcinoid tumors: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4100-4100.	1.6	2
41	Neuroendocrine Tumors of Unknown Primary. <i>JAMA Surgery</i> , 2014, 149, 889.	4.3	18
42	B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas. <i>Cancer Cell</i> , 2014, 25, 809-821.	16.8	245
43	Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15004-e15004.	1.6	4
44	Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 724-764.	4.9	157
45	Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 312-312.	1.6	2
46	Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2011, 29, 934-943.	1.6	280
47	Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 3403-3410.	1.6	596
48	Maximizing the Potential of Bevacizumab in Cancer Treatment. <i>Oncologist</i> , 2004, 9, 36-42.	3.7	78